Loading...
49 colchicine COVID-19 controlled studies, 25 RCTs
37% improvement
for early treatment, RR
0.63
[0.15-2.65]
https://c19early.org/ometa.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hunt
68%
0.32 [0.15-0.67]
death
Improvement, RR [CI]
Treatment
Control
Hassan (RCT)
-40%
1.40 [0.48-4.12]
hosp.
7/50
5/50
Hassan (RCT)
4%
0.96 [0.68-1.37]
no recov.
27/50
28/50
GRECCO-19
Deftereos (RCT)
77%
0.23 [0.03-1.97]
death
1/55
4/50
GRECCO-19
Deftereos (RCT)
82%
0.18 [0.02-1.50]
ventilation
1/55
5/50
GRECCO-19
Deftereos (RCT)
87%
0.13 [0.01-0.97]
progression
1/55
7/50
Lopes (DB RCT)
80%
0.20 [0.01-4.03]
death
0/36
2/36
Lopes (DB RCT)
50%
0.50 [0.10-2.56]
ICU
2/36
4/36
Lopes (DB RCT)
22%
0.78 [0.64-0.94]
hosp. time
36 (n)
36 (n)
Brunetti (PSM)
73%
0.27 [0.08-0.89]
death
3/33
11/33
Brunetti (PSM)
73%
0.27 [0.08-0.89]
no disch.
3/33
11/33
Scarsi
85%
0.15 [0.06-0.37]
death
122 (n)
140 (n)
Salehzadeh (RCT)
23%
0.77 [0.66-0.90]
hosp. time
50 (n)
50 (n)
Pinzón
35%
0.65 [0.34-1.21]
death
14/145
23/156
Sandhu
42%
0.58 [0.40-0.85]
death
16/34
63/78
Sandhu
53%
0.47 [0.33-0.67]
ventilation
16/34
68/68
Sandhu
42%
0.58 [0.40-0.85]
no disch.
16/34
63/78
Rodriguez-Nava
6%
0.94 [0.61-1.47]
death
16/52
85/261
Mahale
-7%
1.07 [0.59-1.96]
death
11/39
25/95
Valerio Pas.. (ICU)
23%
0.77 [0.31-1.94]
death
5/35
12/30
ICU patients CT1
Valerio Pas.. (ICU)
40%
0.60 [0.38-0.95]
ICU
35 (n)
30 (n)
ICU patients CT1
COLCORONA
Tardif (DB RCT)
44%
0.56 [0.19-1.67]
death
5/2,235
9/2,253
COLCORONA
Tardif (DB RCT)
20%
0.80 [0.62-1.03]
death/hosp.
104/2,235
131/2,253
COLCORONA
Tardif (DB RCT)
47%
0.53 [0.25-1.09]
ventilation
11/2,235
21/2,253
COLCORONA
Tardif (DB RCT)
20%
0.80 [0.61-1.03]
hosp.
101/2,235
128/2,253
Mareev
80%
0.20 [0.01-4.01]
death
0/21
2/22
Mareev
50%
0.50 [0.24-1.04]
no recov.
21 (n)
22 (n)
Mareev
71%
0.29 [0.13-0.63]
no recov.
21 (n)
22 (n)
Mareev
67%
0.33 [0.10-1.07]
no recov.
21 (n)
22 (n)
Mareev
26%
0.74 [0.53-1.04]
hosp. time
21 (n)
22 (n)
García-Posada
57%
0.43 [0.16-0.84]
death
48/99
59/110
CT1
Manenti (PSW)
76%
0.24 [0.09-0.67]
death
71 (n)
70 (n)
Manenti (PSW)
44%
0.56 [0.31-1.00]
no recov.
71 (n)
70 (n)
Mostafaie (RCT)
83%
0.17 [0.02-1.34]
death
1/60
6/60
CT1
Mostafaie (RCT)
35%
0.65 [0.53-0.81]
hosp. time
59 (n)
54 (n)
CT1
RECOVERY
Recovery C.. (RCT)
-1%
1.01 [0.93-1.10]
death
1,173/5,610
1,190/5,730
RECOVERY
Recovery C.. (RCT)
-18%
1.18 [0.99-1.40]
ventilation
259/3,815
228/3,962
RECOVERY
Recovery C.. (RCT)
-2%
1.02 [0.96-1.09]
death/int.
1,344/5,342
1,343/5,469
RECOVERY
Recovery C.. (RCT)
-2%
1.02 [0.97-1.06]
no disch.
1,709/5,610
1,698/5,730
Hueda-Zavaleta
54%
0.46 [0.23-0.91]
death
10/50
109/301
Kevorkian
96%
0.04 [0.01-0.21]
progression
28 (n)
40 (n)
CT1
Gaitán-Dua.. (RCT)
22%
0.78 [0.44-1.36]
death
22/153
28/161
CT1
Pascual-Fi.. (RCT)
80%
0.20 [0.01-4.03]
death
0/52
2/51
Pascual-Fi.. (RCT)
80%
0.20 [0.01-4.03]
ventilation
0/52
2/51
Pascual-Fi.. (RCT)
51%
0.49 [0.09-2.56]
ICU
2/52
4/51
Pascual-Fi.. (RCT)
87%
0.13 [0.01-0.71]
7-point status
3/52
7/51
Pascual-Fi.. (RCT)
80%
0.20 [0.01-4.03]
7-point status
0/52
2/51
Pascual-Fi.. (RCT)
-15%
1.15 [0.87-1.51]
hosp. time
52 (n)
51 (n)
Dorward (RCT)
70%
0.30 [0.01-7.37]
death
0/156
1/120
Dorward (RCT)
-30%
1.30 [0.42-3.84]
death/hosp.
6/156
4/133
Dorward (RCT)
22%
0.78 [0.30-1.73]
death/hosp.
6/156
119/1,145
Dorward (RCT)
-6%
1.06 [0.81-1.39]
no recov.
156 (n)
133 (n)
Absalón-.. (DB RCT)
29%
0.71 [0.21-2.40]
death
4/56
6/60
Absalón-.. (DB RCT)
17%
0.83 [0.35-1.93]
progression
56 (n)
60 (n)
Absalón-.. (DB RCT)
-13%
1.13 [0.76-1.66]
no recov.
56 (n)
60 (n)
Diaz (RCT)
12%
0.88 [0.70-1.12]
death
131/640
142/639
Diaz (RCT)
17%
0.83 [0.67-1.02]
death/int.
160/640
184/639
Diaz (RCT)
52%
0.48 [0.18-1.27]
death/int.
6/93
13/102
Diaz (RCT)
17%
0.83 [0.64-1.07]
death
98/515
140/634
Diaz (RCT)
25%
0.75 [0.60-0.95]
death/int.
117/515
181/634
Alsultan (RCT)
36%
0.64 [0.20-2.07]
death
3/14
7/21
Karakaş
13%
0.87 [0.46-1.64]
death
16/165
19/171
Karakaş
16%
0.84 [0.55-1.29]
ICU
30/165
37/171
Karakaş
25%
0.75 [0.65-0.87]
hosp. time
165 (n)
171 (n)
Pourdowlat (RCT)
73%
0.27 [0.11-0.71]
hosp.
5/102
18/100
Pourdowlat (RCT)
38%
0.62 [0.41-0.94]
no recov.
89 (n)
63 (n)
Pourdowlat (RCT)
22%
0.78 [0.60-1.00]
no recov.
89 (n)
63 (n)
Gorial (RCT)
67%
0.33 [0.04-3.14]
death
1/80
3/80
Gorial (RCT)
63%
0.37 [0.21-0.67]
no recov.
80 (n)
80 (n)
STRUCK
Pimenta B.. (RCT)
79%
0.21 [0.01-4.05]
death
0/14
2/16
STRUCK
Pimenta B.. (RCT)
85%
0.15 [0.01-2.69]
no improv.
0/14
3/16
Jalal (RCT)
24%
0.76 [0.62-0.93]
hosp. time
36 (n)
44 (n)
Cecconi (DB RCT)
29%
0.71 [0.28-1.79]
death
7/119
10/120
Cecconi (DB RCT)
50%
0.50 [0.18-1.43]
ventilation
5/119
10/120
Cecconi (DB RCT)
21%
0.79 [0.38-1.67]
ICU
11/119
14/120
Cecconi (DB RCT)
15%
0.85 [0.50-1.43]
NIV/ICU/vent./death
21/119
25/120
ACT inpatient
Eikelboom (RCT)
-8%
1.08 [0.91-1.29]
death
264/1,304
249/1,307
ACT inpatient
Eikelboom (RCT)
-4%
1.04 [0.90-1.21]
progression
368/1,304
356/1,307
ACT inpatient
Eikelboom (RCT)
2%
0.98 [0.82-1.17]
progression
246/1,304
252/1,307
ACT outpatient
Eikelboom (RCT)
-9%
1.09 [0.48-2.47]
death
12/1,939
11/1,942
ACT outpatient
Eikelboom (RCT)
-2%
1.02 [0.72-1.43]
death/hosp.
66/1,939
65/1,942
ACT outpatient
Eikelboom (RCT)
-2%
1.02 [0.71-1.45]
hosp.
62/1,939
61/1,942
COLVID-19
Perricone (RCT)
-36%
1.36 [0.45-4.11]
death
7/77
5/75
COLVID-19
Perricone (RCT)
-7%
1.07 [0.48-2.37]
progression
11/77
10/75
COLVID-19
Perricone (RCT)
-30%
1.30 [0.30-5.61]
ventilation
4/77
3/75
COLVID-19
Perricone (RCT)
76%
0.24 [0.03-2.13]
ICU
1/77
4/75
COLVID-19
Perricone (RCT)
4%
0.96 [0.79-1.17]
hosp. time
77 (n)
75 (n)
Rahman (DB RCT)
71%
0.29 [0.10-0.92]
death
4/146
13/146
Rahman (DB RCT)
71%
0.29 [0.10-0.92]
progression
4/146
13/146
Rahman (DB RCT)
61%
0.39 [0.08-2.02]
death
2/146
5/146
Rahman (DB RCT)
51%
0.49 [0.09-2.68]
ventilation
2/146
4/146
Rahman (DB RCT)
56%
0.44 [0.13-1.43]
progression
4/146
9/146
Kasiri (DB RCT)
7%
0.93 [0.32-2.69]
death
6/55
6/51
Kasiri (DB RCT)
7%
0.93 [0.32-2.69]
ventilation
6/55
6/51
Kasiri (DB RCT)
-24%
1.24 [0.57-2.69]
ICU
12/55
9/51
Kasiri (DB RCT)
28%
0.72 [0.29-1.79]
no recov.
7/55
9/51
Kasiri (DB RCT)
12%
0.88 [0.55-1.43]
no recov.
20/55
21/51
Kasiri (DB RCT)
14%
0.86 [0.73-1.01]
recov. time
55 (n)
51 (n)
Sunil Naik (RCT)
-169%
2.69 [0.11-64.6]
death
1/62
0/43
Sunil Naik (RCT)
-108%
2.08 [0.22-19.3]
progression
3/62
1/43
Sunil Naik (RCT)
7%
0.93 [0.82-1.04]
no recov.
62 (n)
43 (n)
Sunil Naik (RCT)
15%
0.85 [0.72-1.01]
no recov.
49/62
40/43
Sunil Naik (RCT)
24%
0.76 [0.60-0.95]
no recov.
62 (n)
43 (n)
COLSTAT
Shah (RCT)
-75%
1.75 [0.53-5.83]
death
7/125
4/125
CT1
COLSTAT
Shah (RCT)
-100%
2.00 [0.51-7.82]
death
6/125
3/125
CT1
COLSTAT
Shah (RCT)
-200%
3.00 [0.62-14.6]
ventilation
6/125
2/125
CT1
COLSTAT
Shah (RCT)
-46%
1.46 [0.76-2.83]
severe case
19/125
13/125
CT1
COLSTAT
Shah (RCT)
-73%
1.73 [0.86-3.48]
severe case
19/125
11/125
CT1
Villamañán
42%
0.58 [0.33-0.96]
death
19/111
32/111
Madrid-García
-37%
1.37 [0.48-3.90]
death
n/a
n/a
Madrid-García
-137%
2.37 [0.64-8.73]
hosp.
n/a
n/a
Ozcifci
4%
0.96 [0.75-1.22]
cases
130/616
85/421
Monserrat .. (PSM)
80%
0.20 [0.02-0.93]
death
n/a
n/a
Topless
23%
0.77 [0.56-1.07]
death
population-based cohort
Oztas
-406%
5.06 [0.59-43.2]
hosp.
5/635
1/643
Oztas
-73%
1.73 [0.96-3.11]
symp. case
29/635
17/643
Oztas
-24%
1.24 [0.81-1.92]
cases
43/635
35/643
Avanoglu Guler
79%
0.21 [0.04-0.83]
oxygen
6/66
3/7
Correa-Rodríguez
-150%
2.50 [0.10-60.6]
oxygen
1/163
0/81
Correa-Rodríguez
-150%
2.50 [0.10-60.6]
hosp.
1/163
0/81
Correa-Rodríguez
7%
0.93 [0.51-1.70]
no recov.
13/24
7/12
Correa-Rodríguez
1%
0.99 [0.52-1.88]
cases
24/163
12/81
Sáenz-Aldea
-8%
1.08 [0.76-1.53]
hosp.
case control
Sáenz-Aldea
-12%
1.12 [0.91-1.37]
cases
case control
Chevalier
-28%
1.28 [0.51-2.35]
death
5/21
111/569
Chevalier
8%
0.92 [0.36-1.78]
hosp.
15/116
180/1,097
Colchicine COVID-19 outcomes
c19 early .org Sep 2023
1 CT: study uses combined treatment
Favors colchicine
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit